June 2013 Better than Ever Is Not Good Enough By Erica Lessem NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2013. Introduction In December 2012, tuberculosis (TB) treatment reached a historic…
June 2013 By Colleen Daniels Currently, smear microscopy and mycobacterial culture are the most widely used diagnostic tests, but microscopy, though relatively fast, is too inaccurate—missing over half of cases1—while culture is accurate but slow, taking from two to eight…
June 2013 By Karyn Kaplan As rich countries prepare for a hepatitis C virus (HCV) treatment revolution, people in low- and middle-income countries (LMICs) remain without access to information, prevention tools, diagnostics, care, and treatment. A growing movement of global…
Streamlining HCV Treatment By Tracy Swan Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations of direct-acting antivirals (DAAs) have pushed cure rates in HCV genotype 1 to over 90 percent. Still, we are…
June 2013 By Tracy Swan Thanks to Jules Levin The pace of, and progress in, hepatitis C virus (HCV) drug development are astonishing. In April 2011, proof-of-concept for safe, effective, peginterferon-free HCV treatment was announced. Since then, numerous trials have…
January 2014 Update Research Toward a Cure At the close of 2013 there was another update from Timothy Henrich about the Boston area stem cell transplant cases, revealing that the respite from HIV replication was relatively short-lived. Henrich reported in…
June 2013 By Polly Clayden Last year’s Pipeline Report saw the addition of a new chapter exploring research into antiretroviral treatment optimization. This strategy includes the optimization of approved compounds, and possible future opportunities with those in late-stage development. This…
June 2013 By Polly Clayden The last Pipeline Report described a bumper year for pediatric antiretroviral approvals. This one reports after a year in which new approvals were fewer and far between. Although the pipeline for children continues to look…
June 2013 By Simon Collins and Tim Horn NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2013. Introduction The model of pricing newly approved antiretrovirals (ARVs) higher than current drugs is…
June 2013 2013 HIV pipeline executive summary The 2013 HIV pipeline comprises adult and pediatric antiretroviral therapy (ART) development and dose-optimization research as well as antiretroviral preventive technologies, research toward a cure, and immune-based and gene therapies. Adult and pediatric…